Neuren's Royalties From Daybue Sales Beat Bull's Forecast -- Market Talk

Dow Jones

03/04

2308 ET - Royalty revenue flowing to Neuren Pharmaceuticals from U.S. sales of the Daybue treatment for Rett Syndrome last year beat Macquarie's expectations. Acadia Pharmaceuticals, Neuren's partner, said U.S. net sales of Daybue totaled US$391 million in 2025. That was above the US$350 million of sales achieved in 2024. Macquarie says the sales outcome translates to A$65.0 million in royalties for Neuren, up 15% on year. This is 1.5% higher than its forecast of A$64.0 million. "Royalty revenue ahead of expectations, driven by growth in new patient prescriptions," Macquarie says. "Neuren's strong cash position enables pipeline acceleration, potentially providing significant long-term upside." It has an outperform call on Neuren. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

March 03, 2026 18:08 ET (23:08 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2616137072"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616137072\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616137072?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 07:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616137072","market":"nz","top_or_hot":-1,"title":"Neuren's Royalties From Daybue Sales Beat Bull's Forecast -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2308 ET - Royalty revenue flowing to <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> from U.S. sales of the Daybue treatment for Rett Syndrome last year beat <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a>'s expectations. Acadia Pharmaceuticals, Neuren's partner, said U.S. net sales of Daybue totaled US$391 million in 2025. That was above the US$350 million of sales achieved in 2024. Macquarie says the sales outcome translates to A$65.0 million in royalties for Neuren, up 15% on year. This is 1.5% higher than its forecast of A$64.0 million. \"Royalty revenue ahead of expectations, driven by growth in new patient prescriptions,\" Macquarie says. \"Neuren's strong cash position enables pipeline acceleration, potentially providing significant long-term upside.\" It has an outperform call on Neuren. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 03, 2026 18:08 ET (23:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neuren's Royalties From Daybue Sales Beat Bull's Forecast -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuren's Royalties From Daybue Sales Beat Bull's Forecast -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-03-04 07:08</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2308 ET - Royalty revenue flowing to <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> from U.S. sales of the Daybue treatment for Rett Syndrome last year beat <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a>'s expectations. Acadia Pharmaceuticals, Neuren's partner, said U.S. net sales of Daybue totaled US$391 million in 2025. That was above the US$350 million of sales achieved in 2024. Macquarie says the sales outcome translates to A$65.0 million in royalties for Neuren, up 15% on year. This is 1.5% higher than its forecast of A$64.0 million. \"Royalty revenue ahead of expectations, driven by growth in new patient prescriptions,\" Macquarie says. \"Neuren's strong cash position enables pipeline acceleration, potentially providing significant long-term upside.\" It has an outperform call on Neuren. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 03, 2026 18:08 ET (23:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"製藥","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2616137072","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616137072","pubTimestamp":1772579280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2308 ET - Royalty revenue flowing to Neuren Pharmaceuticals from U.S. sales of the Daybue treatment for Rett Syndrome last year beat Macquarie's expectations. Acadia Pharmaceuticals, Neuren's partner, said U.S. net sales of Daybue totaled US$391 million in 2025. That was above the US$350 million of sales achieved in 2024. Macquarie says the sales outcome translates to A$65.0 million in royalties for Neuren, up 15% on year. This is 1.5% higher than its forecast of A$64.0 million. \"Royalty revenue ahead of expectations, driven by growth in new patient prescriptions,\" Macquarie says. \"Neuren's strong cash position enables pipeline acceleration, potentially providing significant long-term upside.\" It has an outperform call on Neuren. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","NEU.AU":"NEUREN PHARMACEUTICALS LTD","BK7508":"医药生物股"},"translate_title":"Neuren从Daybue销售中获得的特许权使用费超出了公牛的预期——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEU.AU":0.9},"content_text":"2308 ET - Royalty revenue flowing to Neuren Pharmaceuticals from U.S. sales of the Daybue treatment for Rett Syndrome last year beat Macquarie's expectations. Acadia Pharmaceuticals, Neuren's partner, said U.S. net sales of Daybue totaled US$391 million in 2025. That was above the US$350 million of sales achieved in 2024. Macquarie says the sales outcome translates to A$65.0 million in royalties for Neuren, up 15% on year. This is 1.5% higher than its forecast of A$64.0 million. \"Royalty revenue ahead of expectations, driven by growth in new patient prescriptions,\" Macquarie says. \"Neuren's strong cash position enables pipeline acceleration, potentially providing significant long-term upside.\" It has an outperform call on Neuren. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2026 18:08 ET (23:08 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}